These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 25674857)

  • 21. Additional lesions detected in therapeutic scans with 177Lu-DOTATATE reflect higher affinity of 177Lu-DOTATATE for somatostatin receptors.
    Mirzaei S; Bastati B; Lipp RW; Knoll P; Zojer N; Ludwig H
    Oncology; 2011; 80(5-6):326-9. PubMed ID: 21791941
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Renal and hematological toxicity in patients of neuroendocrine tumors after peptide receptor radionuclide therapy with 177Lu-DOTATATE.
    Gupta SK; Singla S; Bal C
    Cancer Biother Radiopharm; 2012 Nov; 27(9):593-9. PubMed ID: 23009580
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Metastatic olfactory neuroblastoma invading a radiation-induced meningioma.
    Dimou J; Mitchell RA; Tsui A; Kavar B; Kaye AH
    J Clin Neurosci; 2011 Sep; 18(9):1249-51. PubMed ID: 21752653
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Resolution of Hyperreninemia, Secondary Hyperaldosteronism, and Hypokalemia With 177Lu-DOTATATE Induction and Maintenance Peptide Receptor Radionuclide Therapy in a Patient With Pancreatic Neuroendocrine Tumor.
    Makis W; McCann K; Riauka TA; McEwan AJ
    Clin Nucl Med; 2015 Nov; 40(11):880-4. PubMed ID: 26359564
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Amino acid extravasation: a rare red flag to keep in mind during peptide receptor radioligand therapy (PRRT) with [177Lu]Lu-DOTATATE.
    Divband G; Alavi SH; Adinehpour Z; Kalantari F; Zarehparvar Moghadam S
    Nucl Med Rev Cent East Eur; 2022; 25(2):136-137. PubMed ID: 35848524
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safety and Effectiveness of 177Lu-DOTATATE Peptide Receptor Radionuclide Therapy After Regional Hepatic Embolization in Patients With Somatostatin-Expressing Neuroendocrine Tumors.
    Hamiditabar M; Ali M; Bolek L; Vahdati G; Tworowska I; Delpassand ES
    Clin Nucl Med; 2017 Nov; 42(11):822-828. PubMed ID: 28832377
    [TBL] [Abstract][Full Text] [Related]  

  • 27. TeleNEN as a telemedicine model for neuroendocrine neoplasm management in case of Meckel's diverticulum NET.
    Kunikowska J; Zemczak A; Górska M; Matyskiel R; Słodkowski M; Łoń I; Chrapko B; Kos-Kudła B; Królicki L
    Endokrynol Pol; 2018; 69(3):313-317. PubMed ID: 29952421
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Esthesioneuroblastoma as an unusual cause for dystopia.
    Kamath VB; Sowmya V; Ballal CK; Mendonca N
    Orbit; 2013 Dec; 32(6):392-4. PubMed ID: 24063411
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Quality of life in patients with midgut NET following peptide receptor radionuclide therapy.
    Marinova M; Mücke M; Fischer F; Essler M; Cuhls H; Radbruch L; Ghaei S; Conrad R; Ahmadzadehfar H
    Eur J Nucl Med Mol Imaging; 2019 Oct; 46(11):2252-2259. PubMed ID: 31338547
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Acute Pancreatitis Following Peptide Receptor Radionuclide Therapy: An Unusual Adverse Event.
    Karfis I; Marin G; Machiels G; Hendlisz A; Flamen P
    Clin Nucl Med; 2018 Jul; 43(7):e232-e233. PubMed ID: 29762236
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Peptide Receptor Radionuclide Therapy for Recurrent Olfactory Neuroblastoma After Cranioplasty for Surgical Infection: A Case Report.
    Suzuki H; Haimoto S; Inaba Y; Tachibana H; Takanari K; Ando M; Yoshizawa K; Hanai N
    Anticancer Res; 2023 Dec; 43(12):5723-5728. PubMed ID: 38030203
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Complete Remission of Metastatic Neuroendocrine Paragastric Carcinoma After "Neoadjuvant" Peptide Receptor Radionuclide Therapy and Surgery.
    Schmidt MC; Uhrhan K; Fischer T; Schmitz S; Markiefka B; Drzezga A; Stippel D
    Clin Nucl Med; 2015 Aug; 40(8):667-9. PubMed ID: 26053706
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Different technical possibilities of post-therapeutic tandem 90Y/ /177Lu-DOTATATE imaging.
    Kunikowska J; Bajera A; Sawicka M; Czwarnowski P; Pawłowicz B; Aksamit D; Pawlak D; Królicki L
    Nucl Med Rev Cent East Eur; 2013; 16(2):70-4. PubMed ID: 24068636
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Olfactory esthesioneuroblastoma: scintigraphic expression of somatostatin receptors].
    García Vicente A; García Del Castillo E; Soriano Castrejón A; Alonso Farto J
    Rev Esp Med Nucl; 1999 Oct; 18(5):367-70. PubMed ID: 10562667
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Performance of 177Lu-DOTATATE-based peptide receptor radionuclide therapy in metastatic gastroenteropancreatic neuroendocrine tumor: a multiparametric response evaluation correlating with primary tumor site, tumor proliferation index, and dual tracer imaging characteristics.
    Thapa P; Ranade R; Ostwal V; Shrikhande SV; Goel M; Basu S
    Nucl Med Commun; 2016 Oct; 37(10):1030-7. PubMed ID: 27243215
    [TBL] [Abstract][Full Text] [Related]  

  • 36. High clinical and morphologic response using
    Kong G; Callahan J; Hofman MS; Pattison DA; Akhurst T; Michael M; Eu P; Hicks RJ
    Eur J Nucl Med Mol Imaging; 2017 Mar; 44(3):476-489. PubMed ID: 27678267
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Surgical treatment in a case of extensive esthesioneuroblastoma in 77 years old female].
    Czak W
    Otolaryngol Pol; 2004; 58(5):989-90. PubMed ID: 15732788
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dose response of pancreatic neuroendocrine tumors treated with peptide receptor radionuclide therapy using 177Lu-DOTATATE.
    Ilan E; Sandström M; Wassberg C; Sundin A; Garske-Román U; Eriksson B; Granberg D; Lubberink M
    J Nucl Med; 2015 Feb; 56(2):177-82. PubMed ID: 25593115
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Favorable Response of Metastatic Merkel Cell Carcinoma to Targeted 177Lu-DOTATATE Therapy: Will PRRT Evolve to Become an Important Approach in Receptor-Positive Cases?
    Basu S; Ranade R
    J Nucl Med Technol; 2016 Jun; 44(2):85-7. PubMed ID: 26471333
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ectopic Corticotropin-Producing Neuroendocrine Tumor of the Pancreas Treated With 177Lu DOTATATE Induction and Maintenance Peptide Receptor Radionuclide Therapy.
    Makis W; McCann K; Riauka TA; McEwan AJ
    Clin Nucl Med; 2016 Jan; 41(1):50-2. PubMed ID: 26359569
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.